Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy

Kleinberg, Lawrence

doi:10.2147/ppa.s93020

Cited by 24 publications

(14 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Bioresorbable Passive Implantsmentioning

confidence: 99%

“…For example, hydrogel/patch‐type devices have been developed for intracranial sustained drug release. Patch‐type bioresorbable drug reservoirs (e.g., Gliadel wafer; Figure h) can be applied to the treatment of brain tumors. In brain tumors, drug delivery via the conventional routes is difficult owing to the blood‐brain‐barrier.…”

Section: Bioresorbable Passive Implantsmentioning

confidence: 99%

See 1 more Smart Citation

Bioresorbable Electronic Implants: History, Materials, Fabrication, Devices, and Clinical Applications

Doo

Kang

Lee

et al. 2019

Adv Healthcare Materials

102

View full text Add to dashboard Cite

Medical implants, either passive implants for structural support or implantable devices with active electronics, have been widely used for the diagnosis and treatment of various diseases and clinical issues. These implants offer various functions, including mechanical support of biological structures in orthopedic and dental applications, continuous electrophysiological monitoring and feedback of electrical stimulation in neuronal and cardiac applications, and controlled drug delivery while maintaining arterial structure in drug‐eluting stents. Although these implants exhibit long‐term biocompatibility, surgery for their retrieval is often required, which imposes physical, biological, and economical burdens on the patients. Therefore, as an alternative to such secondary surgeries, bioresorbable implants that disappear after a certain period of time inside the body, including bioresorbable active electronics, have been highlighted recently. This review first discusses the historical background of medical implants and briefly define related terminology. Representative examples of non‐degradable medical implants for passive structural support and/or for diagnosis and therapy with active electronics are also provided. Then, recent progress in bioresorbable active implants composed of biosignal sensors, actuators for therapeutics, wireless power supply components, and their integrated systems are reviewed. Finally, clinical applications of these bioresorbable electronic implants are exemplified with brief conclusion and future outlook.

show abstract

Section: Bioresorbable Passive Implantsmentioning

confidence: 99%

Section: Bioresorbable Passive Implantsmentioning

confidence: 99%

Bioresorbable Electronic Implants: History, Materials, Fabrication, Devices, and Clinical Applications

Doo

Kang

Lee

et al. 2019

Adv Healthcare Materials

102

View full text Add to dashboard Cite

show abstract

“…These wafers are implants containing carmustine and a biodegradable copolymer (polifeprosan-a polyanhydride copolymer consisting of poly [bis (p-carboxyphenoxy)] propane and sebacic acid at a 20:80 molar ratio), to control the release rate of carmustine. These wafers are white to pale yellow, ~1.45-cm in diameter and with a thickness of 1-mm (25). Carmustine causes cross-links in DNA and RNA, inhibiting DNA synthesis, RNA production and translation.…”

Section: Introductionmentioning

confidence: 99%

Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)

et al. 2021

View full text Add to dashboard Cite

Due to its localisation, rapid onset, high relapse rate and resistance to most currently available treatment methods, glioblastoma multiforme (GBM) is considered to be the deadliest type of all gliomas. Although surgical resection, chemotherapy and radiotherapy are among the therapeutic strategies used for the treatment of GBM, the survival rates achieved are not satisfactory, and there is an urgent need for novel effective therapeutic options. In addition to single-target therapy, multi-target therapies are currently under development. Furthermore, drugs are being optimised to improve their ability to cross the blood-brain barrier. In the present review, the main strategies applied for GBM treatment in terms of the most recent therapeutic agents and approaches that are currently under pre-clinical and clinical testing were discussed. In addition, the most recently reported experimental data following the testing of novel therapies, including stem cell therapy, immunotherapy, gene therapy, genomic correction and precision medicine, were reviewed, and their advantages and drawbacks were also summarised.

show abstract

“…It should be pointed out that GBM is a fatal primary brain tumor with a median survival of 18 months (16). GBM is characterized by a rapid invasion and relapse.…”

Section: Introductionmentioning

confidence: 99%

“…The routine methods of GBM treatment include maximal safe resection of the tumor, partial brain radiotherapy and oral or intravenous chemotherapy (16). A more effective solution is combination therapy of maximal safe resection, partial radiotherapy and local chemotherapy by implantable drug formulation.…”

Section: Introductionmentioning

confidence: 99%

Designing Biodegradable Wafers Based on Poly(L-lactide-co-glycolide) and Poly(glycolide-co-ε-caprolactone) for the Prolonged and Local Release of Idarubicin for the Therapy of Glioblastoma Multiforme

et al. 2020

View full text Add to dashboard Cite

Purpose The blood-brain barrier limits the application of idarubicin in the therapy of glioblastoma multiforme. Biodegradable, intracranial wafers with prolonged release may increase therapy efficiency. Methods Blank wafers, wafers containing 5% w/w and 10% w/w of idarubicin were formulated by solution casting from poly(L-lactide-co-glycolide) and poly(glycolide-co-ε-caprolactone). The following methods were used: NMR, GPC, DSC, FTIR, AFM, UV-VIS, and a viability and proliferation assay for idarubicin action (U87MG cell line). Results Wafers showed a surface with numerous immersions and hills. A lack of interactions between idarubicin and the copolymers was observed. The substance was entrapped in the matrix and released in two phases for all wafers with the appropriate bolus and maintenance dose. The burst effect was observed for all wafers, however, the biggest bolus for poly(L-lactide-co-glycolide) wafers containing 5% w/w of idarubicin was noted. The stable and steady degradation of poly(glycolide-co-ε-caprolactone) wafers containing 5% w/w of idarubicin ensures the most optimal release profile and high inhibition of proliferation. Conclusions Copolymer wafers with idarubicin are an interesting proposition with great potential for the local treatment of glioblastoma multiforme. The release rate and dose may be regulated by the amount and kind of wafers for various effects.

show abstract

Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy

Cited by 24 publications

References 71 publications

Bioresorbable Electronic Implants: History, Materials, Fabrication, Devices, and Clinical Applications

Bioresorbable Electronic Implants: History, Materials, Fabrication, Devices, and Clinical Applications

Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)

Designing Biodegradable Wafers Based on Poly(L-lactide-co-glycolide) and Poly(glycolide-co-ε-caprolactone) for the Prolonged and Local Release of Idarubicin for the Therapy of Glioblastoma Multiforme

Contact Info

Product

Resources

About